Novel combination of pozelimab and cemdisiran (poze-cemdi) achieved greater control of intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria compared to ravulizumab

Head-to-head exploratory cohort of a phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydrogenase (ldh) levels, compared to standard-of-care ravulizumab
REGN Ratings Summary
REGN Quant Ranking